Susan M Chang1, Hans Messersmith2, Manmeet Ahluwalia3, David Andrews4, Priscilla K Brastianos5, Laurie E Gaspar6, Na Tosha N Gatson7, Justin T Jordan5, Mustafa Khasraw8, Andrew B Lassman9, Julia Maues10, Maciej Mrugala11, Jeffrey Raizer12, David Schiff13, Glen Stevens3, Ashley Sumrall14, Martin van den Bent15, Michael A Vogelbaum3. 1. 1 University of California, San Francisco, San Francisco, CA. 2. 2 American Society of Clinical Oncology, Alexandria, VA. 3. 3 Cleveland Clinic, Cleveland, OH. 4. 4 Thomas Jefferson University, Philadelphia, PA. 5. 5 Massachusetts General Hospital, Boston, MA. 6. 6 University of Colorado School of Medicine, Denver, CO. 7. 7 Geisinger Neuroscience and Cancer Institutes, Danville, PA. 8. 8 The University of Sydney, Sydney, NSW, Australia. 9. 9 Columbia University Irving Medical Center, New York, NY. 10. 10 Georgetown Breast Cancer Advocates, Washington, DC. 11. 11 Mayo Clinic, Phoenix, AZ. 12. 12 Northwestern University, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. 13. 13 University of Virginia Medical Center, Charlottesville, VA. 14. 14 Levine Cancer Institute, Charlotte, NC. 15. 15 Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Abstract
PURPOSE: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The Expert Panel voted to endorse the two guidelines, and ASCO and Society for Neuro-Oncology (SNO) independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS: The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based on the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines with minor alterations. RECOMMENDATIONS: Key recommendations include the following: prophylactic antiepileptic drugs were not recommended for routine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases. Additional information is available at www.asco.org/neurooncology-guidelines .
PURPOSE: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The Expert Panel voted to endorse the two guidelines, and ASCO and Society for Neuro-Oncology (SNO) independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS: The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based on the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines with minor alterations. RECOMMENDATIONS: Key recommendations include the following: prophylactic antiepileptic drugs were not recommended for routine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases. Additional information is available at www.asco.org/neurooncology-guidelines .
Authors: Kaveh G Shojania; Margaret Sampson; Mohammed T Ansari; Jun Ji; Steve Doucette; David Moher Journal: Ann Intern Med Date: 2007-07-16 Impact factor: 25.391
Authors: Laurie E Gaspar; Roshan S Prabhu; Alia Hdeib; D Jay McCracken; George F Lasker; Michael W McDermott; Steven N Kalkanis; Jeffrey J Olson Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Jonathan H Sherman; Simon S Lo; Tom Harrod; Alia Hdeib; Yiping Li; Timothy Ryken; Jeffrey J Olson Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Brian V Nahed; Christopher Alvarez-Breckenridge; Priscilla K Brastianos; Helen Shih; Andrew Sloan; Mario Ammirati; John S Kuo; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson Journal: Neurosurgery Date: 2019-03-01 Impact factor: 4.654
Authors: Kathryn C Arbour; Laura Mezquita; Niamh Long; Hira Rizvi; Edouard Auclin; Andy Ni; Gala Martínez-Bernal; Roberto Ferrara; W Victoria Lai; Lizza E L Hendriks; Joshua K Sabari; Caroline Caramella; Andrew J Plodkowski; Darragh Halpenny; Jamie E Chaft; David Planchard; Gregory J Riely; Benjamin Besse; Matthew D Hellmann Journal: J Clin Oncol Date: 2018-08-20 Impact factor: 44.544
Authors: Susan M Chang; Hans Messersmith; Manmeet Ahluwalia; David Andrews; Priscilla K Brastianos; Laurie E Gaspar; Na Tosha N Gatson; Justin T Jordan; Mustafa Khasraw; Andrew B Lassman; Julia Maues; Maciej Mrugala; Jeffrey Raizer; David Schiff; Glen Stevens; Ashley Sumrall; Martin Van den Bent; Michael A Vogelbaum Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Jennifer K Matsui; Haley K Perlow; Cyril Baiyee; Alex R Ritter; Mark V Mishra; Joseph A Bovi; Vinai Gondi; Paul D Brown; Ashlee R Loughan; Heather E Leeper; Erica Dawson; Joshua D Palmer Journal: Cancers (Basel) Date: 2022-09-01 Impact factor: 6.575